Efficacy and Safety of Immunotherapy with Interferon-Gamma in the Management of Chronic Sulfur Mustard-Induced Cutaneous Complications: Comparison with Topical Betamethasone 1%
Table 1
Effects of IFN-γ versus betamethasone 0.1% on the evaluated efficacy measures.
IFN-γ
value
Betamethasone 0.1%
value
Pretrial
Posttrial
Pretrial
Posttrial
DLQI
20.80 ± 0.88
8.20 ± 0.48
<0.001
21.88 ± 0.77
17.18 ± 1.28
<0.001
SCORAD-A
68.58 ± 4.47
29.05 ± 3.67
<0.001
44.15 ± 2.07
35.82 ± 2.35
0.004
SCORAD-B
11.35 ± 0.33
4.55 ± 0.34
<0.001
9.12 ± 0.57
8.29 ± 0.59
0.044
SCORAD-C
16.60 ± 1.03
6.10 ± 0.70
<0.001
15.94 ± 0.65
15.41 ± 0.84
>0.05
Objective SCORAD
53.44 ± 1.16
21.73 ± 1.77
<0.001
40.74 ± 1.89
36.19 ± 2.01
0.006
Overall SCORAD
71.44 ± 2.45
23.95 ± 1.78
<0.001
58.31 ± 1.88
51.60 ± 2.75
0.006
Values are expressed as mean ± SEM. DLQI: dermatology life quality index; SCORAD: scoring atopic dermatitis. SCORAD-A, -B, and -C denote extent, intensity, and subjective symptoms of the disorder, respectively.
